Who owns Arrowhead Pharmaceuticals (ARWR)? Superinvestor holders
2 superinvestors of the 157 tracked here hold Arrowhead Pharmaceuticals (ARWR) in their latest 13F filing, with $252.6M between them. Julian and Felix Baker gives it the most weight: 0.81% of the reported portfolio. In their latest reported quarter, Brandon Haley opened a position.
Ray Dalio (founder) and Polen Capital team sold out of it in their latest quarter.
Key facts
- Superinvestors holding it
- 2 of 157
- Biggest holder
- Julian and Felix Baker, $162.4M
- Largest weight
- Julian and Felix Baker, 0.81%of their portfolio
- Combined value
- $252.6M
- Bought last quarter
- 1
- Sold last quarter
- 2
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Julian and Felix BakerBaker Bros. Advisors | 0.81% | $162.4M | 1.99M | No change | 0 | Q2 2026 |
| 2 | Brandon HaleyHolocene Advisors | 0.21% | $90.2M | 1.11M | New | +1.11M | Q2 2026 |
Sold out last quarter
- Ray Dalio (founder)was $6M · Q2 2026
- Polen Capital teamwas $538.9K · Q3 2026
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 0 | — | — | 0 | 1 |
| Q2 2026 | 157 | 2 | 3.1M | $252.6M | 1 | 2 |
| Q1 2026 | 157 | 2 | 2.01M | $125.9M | 0 | 2 |
| Q4 2025 | 157 | 3 | 4.71M | $313M | 1 | 1 |
| Q3 2025 | 157 | 3 | 6.67M | $230M | 1 | 1 |
| Q2 2025 | 157 | 3 | 6.19M | $97.8M | 1 | 0 |
| Q1 2025 | 156 | 2 | 5.25M | $66.9M | 0 | 1 |
| Q4 2024 | 156 | 2 | 5.86M | $110.2M | 2 | 0 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Julian and Felix Baker | · | 1.99M | 1.99M | 2.18M | 1.67M | 939.17K | — | — |
| Brandon Haley | · | 1.11M | — | — | — | — | — | — |
| Andrew Spokes | — | — | 15.8K | 15.8K | 15.8K | 15.8K | 15.8K | 628.8K |
| David Greenspan | — | — | — | 2.52M | 4.98M | 5.23M | 5.23M | 5.23M |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own ARWR?
In their latest 13F filings: Julian and Felix Baker (0.81% of the portfolio, $162.4M), Brandon Haley (0.21% of the portfolio, $90.2M).
Who bought ARWR last quarter?
Brandon Haley (new position). “Last quarter” is each investor's latest reported quarter.
Who sold ARWR last quarter?
Sold out entirely: Ray Dalio (founder) (was $6M), Polen Capital team (was $538.9K).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns Arrowhead Pharmaceuticals (ARWR)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/ARWR/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to ARWR by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.